Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials.
Journal: Nature communications
Published: September 05, 2023
Outcomes in Pregnant Persons Immunized with a Cell-Based Quadrivalent Inactivated Influenza Vaccine: A Prospective Observational Cohort Study.
Journal: Vaccines
Published: August 05, 2022
A Prospective Cohort Study on Pregnancy Outcomes of Persons Immunized with a Seasonal Quadrivalent Inactivated Influenza Vaccine during Pregnancy.
Journal: Vaccines
Published: August 05, 2022
Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial.
Journal: Pediatrics
Published: July 20, 2022
Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
Journal: The New England journal of medicine
Published: October 13, 2021
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: June 18, 2021
Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study.
Journal: The Lancet. Infectious diseases
Published: April 10, 2020
Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
Journal: Vaccine
Published: May 08, 2018
The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials.
Journal: Chronic obstructive pulmonary diseases (Miami, Fla.)
Published: August 30, 2017
Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema.
Journal: Allergy and asthma proceedings
Published: April 27, 2017
Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema.
Journal: Allergy & rhinology (Providence, R.I.)
Published: April 07, 2017
Last Updated: 09/26/2026